Mavacamten, a first-in-class cardiac myosin inhibitor, demonstrated significant structural and functional improvements in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).
The treatment resulted in a placebo-corrected reduction in maximal left ventricular (LV) wall thickness (-2.1 mm) and LV mass index (-3.8 g/m²), indicating favorable cardiac remodeling.
Markers of diastolic function (E/e’ ratio) and left atrial (LA) mechanics (strain and volume) improved significantly, suggesting reduced intracardiac filling pressures.
While systolic function generally remained preserved in responders, 21.5% of the mavacamten group experienced an LVEF drop below 50%, highlighting the need for vigilant echocardiographic monitoring.
